{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:07:21Z","timestamp":1789448841454,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2011,5,10]]},"abstract":"<jats:sec>\n            <jats:title>Background\u2014<\/jats:title>\n            <jats:p>Lapaquistat acetate is a squalene synthase inhibitor investigated for the treatment of hypercholesterolemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results\u2014<\/jats:title>\n            <jats:p>This report summarizes the phase 2 and 3 results from the lapaquistat clinical program, which was halted at an advanced stage as a result of potential hepatic safety issues. Efficacy and safety data were pooled from 12 studies (n=6151). These were 6- to 96-week randomized, double-blind, parallel, placebo- or active-controlled trials with lapaquistat monotherapy or coadministration with other lipid-altering drugs in dyslipidemic patients, including a large (n=2121) 96-week safety study. All studies included lapaquistat 100 mg daily; 5 included 50 mg; and 1 included 25 mg. The main outcome measures were the percent change in low-density lipoprotein cholesterol, secondary lipid\/metabolic parameters, and overall safety. Lapaquistat 100 mg significantly decreased low-density lipoprotein cholesterol by 21.6% in monotherapy and by 18.0% in combination with a statin. It also reduced other cardiovascular risk markers, such as C-reactive protein. Total adverse events were higher for lapaquistat than placebo, although individual events were generally similar. At 100 mg, there was an increase in alanine aminotransferase value \u22653 times the upper limit of normal on \u22652 consecutive visits (2.0% versus 0.3% for placebo in the pooled efficacy studies; 2.7% versus 0.7% for low-dose atorvastatin in the long-term study). Two patients receiving lapaquistat 100 mg met the Hy Law criteria of alanine aminotransferase elevation plus increased total bilirubin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions\u2014<\/jats:title>\n            <jats:p>Squalene synthase inhibition with lapaquistat acetate, alone or in combination with statins, effectively lowered low-density lipoprotein cholesterol in a dose-dependent manner. Elevations in alanine aminotransferase, combined with a rare increase in bilirubin, presented potential hepatic safety issues, resulting in termination of development. The lapaquistat experience illustrates the current challenges in lipid-altering drug development.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical Trial Registration\u2014<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifiers: NCT00487994, NCT00143663, NCT00143676, NCT00864643, NCT00263081, NCT00286481, NCT00249899, NCT00249912, NCT00813527, NCT00256178, NCT00268697, and NCT00251680.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circulationaha.110.975284","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T03:29:40Z","timestamp":1303788580000},"page":"1974-1985","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":64,"title":["Lapaquistat Acetate"],"prefix":"10.1161","volume":"123","author":[{"given":"Evan A.","family":"Stein","sequence":"first","affiliation":[{"name":"From the Metabolic and Atherosclerosis Research Center, Cincinnati, OH (E.A.S.); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY (H.B.); and Takeda Pharmaceuticals North America, Inc., Deerfield, IL (D.O., J.P., E.P., A.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Bays","sequence":"additional","affiliation":[{"name":"From the Metabolic and Atherosclerosis Research Center, Cincinnati, OH (E.A.S.); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY (H.B.); and Takeda Pharmaceuticals North America, Inc., Deerfield, IL (D.O., J.P., E.P., A.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"O'Brien","sequence":"additional","affiliation":[{"name":"From the Metabolic and Atherosclerosis Research Center, Cincinnati, OH (E.A.S.); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY (H.B.); and Takeda Pharmaceuticals North America, Inc., Deerfield, IL (D.O., J.P., E.P., A.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Pedicano","sequence":"additional","affiliation":[{"name":"From the Metabolic and Atherosclerosis Research Center, Cincinnati, OH (E.A.S.); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY (H.B.); and Takeda Pharmaceuticals North America, Inc., Deerfield, IL (D.O., J.P., E.P., A.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Piper","sequence":"additional","affiliation":[{"name":"From the Metabolic and Atherosclerosis Research Center, Cincinnati, OH (E.A.S.); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY (H.B.); and Takeda Pharmaceuticals North America, Inc., Deerfield, IL (D.O., J.P., E.P., A.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Spezzi","sequence":"additional","affiliation":[{"name":"From the Metabolic and Atherosclerosis Research Center, Cincinnati, OH (E.A.S.); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY (H.B.); and Takeda Pharmaceuticals North America, Inc., Deerfield, IL (D.O., J.P., E.P., A.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.049"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2008.11.011"},{"key":"e_1_3_4_4_2","volume-title":"Manual of Laboratory Operations: Lipid and Lipoprotein Analysis (Revised).","year":"1982","unstructured":"Lipid Research Clinics. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis (Revised). Washington, DC: US Government Printing Office; 1982. US Department of Health and Human Services publication No. (NIH) 75-678."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20081"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(03)01549-8"},{"key":"e_1_3_4_8_2","volume-title":"Paper presented at: Drug-Induced Liver Injury: A National and Global Problem Conference","author":"Temple R","unstructured":"Temple R. Hepatotoxicity through the years: impact on the FDA. Paper presented at: Drug-Induced Liver Injury: A National and Global Problem Conference; February 12\u201313, 2001; Chantilly, VA. www.fda.gov\/Drugs\/ScienceResearch\/ResearchAreas\/ucm091365.htm#temple Accessed October 30, 2009."},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021844"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1211"},{"key":"e_1_3_4_11_2","unstructured":"US Food and Drug Administration Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. July 2009. www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM174090.pdf Accessed October 30 2009."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22633"},{"key":"e_1_3_4_13_2","unstructured":"Lipitor (atorvastatin calcium tablets) [US prescribing information[. Morris Plains NJ: Parke-Davis Division of Warner-Lambert Co; January 1997."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1185\/0300799039117026"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.12.006"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00298-1"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpcardio1250"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.14.1568"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000062990.62034.64"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","unstructured":"Ballantyne CM Houri J Notarbartolo A Melani L Lipka LJ Suresh R Sun S LeBeaut AP Sager PT Veltri EP. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective randomized double-blind trial Circulation. 2003;107(19):2409\u20132415.","DOI":"10.1161\/01.CIR.0000068312.21969.C8"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042000"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02658-9"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.09.090"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400010067008"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.110.975284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:30:05Z","timestamp":1715578205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.110.975284"}},"subtitle":["Development of a Squalene Synthase Inhibitor for the Treatment of Hypercholesterolemia"],"short-title":[],"issued":{"date-parts":[[2011,5,10]]},"references-count":23,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2011,5,10]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.110.975284"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.110.975284","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,10]]},"assertion":[{"value":"2010-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-02-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}